Abstract | BACKGROUND: AIM: To conduct a systematic evidence-based review of pharmacological therapies currently used, or in clinical development, for the treatment of IBS in Europe. The safety and tolerability of these therapies are the subject of an accompanying review. METHODS: A literature search was completed for randomized controlled studies which included adult patients with IBS and an active or placebo control, assessed IBS symptoms, and were published in English between January 1980 and June 2005. The level of evidence for efficacy was graded according to the quality of the trial design and the study outcome. RESULTS: CONCLUSIONS: There is limited evidence for the efficacy, safety and tolerability of therapies currently available in Europe for the treatment of IBS. Overall, there is an absence of pharmacological agents licensed specifically for the treatment of IBS subtypes, and new agents are awaited in Europe that will allow changes in clinical practice to focus on and improve global IBS symptoms.
|
Authors | J Tack, M Fried, L A Houghton, J Spicak, G Fisher |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 24
Issue 2
Pg. 183-205
(Jul 15 2006)
ISSN: 0269-2813 [Print] England |
PMID | 16842448
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Antidepressive Agents
- Cathartics
- Dopamine D2 Receptor Antagonists
- Parasympatholytics
- Serotonin Antagonists
|
Topics |
- Adult
- Antidepressive Agents
(therapeutic use)
- Behavior Therapy
(methods)
- Cathartics
(therapeutic use)
- Dopamine D2 Receptor Antagonists
- Europe
- Humans
- Irritable Bowel Syndrome
(therapy)
- Parasympatholytics
(therapeutic use)
- Serotonin Antagonists
(therapeutic use)
- Treatment Outcome
|